Your browser doesn't support javascript.
loading
The epidemiology and clinical characteristics of myeloproliferative neoplasms in Malaysia.
Yap, Yee Yee; Law, Kian Boon; Sathar, Jameela; Lau, Ngee Siang; Goh, Ai Sim; Chew, Teng Keat; Lim, Soo Min; Menon, Padmini; Guan, Yong Khee; Husin, Azlan Bin; Wong, Lily Lee Lee; Chew, Lee Ping; Salleh, Sinari; Goh, Kim Yen; Leong, Kin Wah; Tan, Sen Mui; Ong, Tee Chuan; Lim, Su Hong; Toh, See Guan; Han, Xavier Sim Yoon; Edmund, Syed Carlo; Tan, Jenq Tzong; Chang, Kian Meng.
Afiliação
  • Yap YY; Department of Haematology, Ampang Hospital, Jalan Mewah Utara, Pandan Mewah, 68000 Ampang, Selangor Malaysia.
  • Law KB; 2Clinical Trial Unit, Clinical Research Centre, Ministry of Health, Ampang, Selangor Malaysia.
  • Sathar J; 2Clinical Trial Unit, Clinical Research Centre, Ministry of Health, Ampang, Selangor Malaysia.
  • Lau NS; Department of Haematology, Ampang Hospital, Jalan Mewah Utara, Pandan Mewah, 68000 Ampang, Selangor Malaysia.
  • Goh AS; 2Clinical Trial Unit, Clinical Research Centre, Ministry of Health, Ampang, Selangor Malaysia.
  • Chew TK; Department of Haematology, Ampang Hospital, Jalan Mewah Utara, Pandan Mewah, 68000 Ampang, Selangor Malaysia.
  • Lim SM; 2Clinical Trial Unit, Clinical Research Centre, Ministry of Health, Ampang, Selangor Malaysia.
  • Menon P; Department of Haematology, Penang General Hospital, George Town, Penang Malaysia.
  • Guan YK; Department of Haematology, Penang General Hospital, George Town, Penang Malaysia.
  • Husin AB; 4Department of Haematology, Hospital Sultanah Aminah, Johor Bahru, Johor Malaysia.
  • Wong LLL; Department of Haematology, Ipoh Hospital, Ipoh, Perak Malaysia.
  • Chew LP; Department of Haematology, Melaka Hospital, Melaka City, Melaka Malaysia.
  • Salleh S; 7Department of Haematology, Hospital Universiti Sains Malaysia, Kota Bharu, Kelantan Malaysia.
  • Goh KY; 8Department of Haematology, Queen Elizabeth Hospital, Kota Kinabalu, Sabah Malaysia.
  • Leong KW; 9Department of Haematology, Sarawak General Hospital, Kuching, Sarawak Malaysia.
  • Tan SM; 10Department of Haematology, Hospital Raja Perempuan Zainab II Kota Bahru, Kota Bahru, Kelantan Malaysia.
  • Ong TC; Department of Haematology, Ampang Putri Hospital, Ampang, Selangor Malaysia.
  • Lim SH; Department of Haematology, Gleneagles Penang Hospital, George Town, Penang Malaysia.
  • Toh SG; Department of Haematology, Ampang Hospital, Jalan Mewah Utara, Pandan Mewah, 68000 Ampang, Selangor Malaysia.
  • Han XSY; 2Clinical Trial Unit, Clinical Research Centre, Ministry of Health, Ampang, Selangor Malaysia.
  • Edmund SC; Department of Haematology, Ampang Hospital, Jalan Mewah Utara, Pandan Mewah, 68000 Ampang, Selangor Malaysia.
  • Tan JT; 2Clinical Trial Unit, Clinical Research Centre, Ministry of Health, Ampang, Selangor Malaysia.
  • Chang KM; Department of Haematology, Gleneagles Penang Hospital, George Town, Penang Malaysia.
Exp Hematol Oncol ; 7: 31, 2018.
Article em En | MEDLINE | ID: mdl-30564475
ABSTRACT

BACKGROUND:

The evolution of molecular studies in myeloproliferative neoplasms (MPN) has enlightened us the understanding of this complex disease consisting of polycythaemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF). The epidemiology is well described in the western world but not in Asian countries like Malaysia. MATERIALS AND

METHODS:

This retrospective national registry of MPN was conducted from year 2009 to 2015 in Malaysia.

RESULTS:

A total of 1010 patients were registered over a period of 5 years. The mean age was 54 years with male predominance. The ethnic distribution revealed that Chinese had a relatively high weighted incidence proportion (43.2%), followed by Indian (23.8%), Malay (15.8%) and other ethnic groups (17.2%). The types of MPN reported were 40.4% of ET (n = 408), 38.1% of PV (n = 385), 9.2% of PMF (n = 93), 3.1% of hypereosinophilic syndrome (HES) (n = 31) and 7.9% of unclassifiable MPN (MPN-U) (n = 80). Splenomegaly was only palpable clinically in 32.2% of patients. The positive JAK2 V617F mutation was present in 644 patients with 46.6% in PV, 36.0% in ET, 9.0% in PMF, and 7.4% in MPN-U, and had significantly lower haemoglobin (p < 0.001), haematocrit (p < 0.001) and white blood cells (WBC) (p < 0.001) than those with negative mutation. Significant differences in platelet and WBC count were detected in ethnic groups and MPN sub-types. There were more arterial thrombosis events seen in those with JAK2 V617F mutation as compared to venous thrombosis events (23.1% vs 4.4%). The bleeding rate was only 6.6%. Among the risk factors, previous thrombosis, old age (≥ 60 years) and hypertension were significantly correlated to positive JAK2 V617F mutation. The arterial thrombosis event is associated with higher presenting HB, HCT and PLT while the bleeding event is associated with lower presenting HB, HCT but higher PLT. The presence of JAK2 V617F mutation is associated with higher risk of arterial thrombosis.

CONCLUSION:

Chinese ethnicity is associated with higher rates of MPN. The history of thrombosis, age ≥ 60 years and hypertension are risk factors that can be correlated to JAK2 V617F mutation. This study is instrumental for policy makers to ensure preventive strategies can be implemented in future.

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2018 Tipo de documento: Article